Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans

This article was originally published in The Gray Sheet

Executive Summary

Beta amyloid positron emission tomography scans to help diagnose dementia would only be covered by Medicare as part of a clinical trial under a proposed national coverage decision. Eli Lilly requested broader coverage for its Amyvid PET imaging agent.

You may also be interested in...



Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD

Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.

Alzheimer’s Community Prepares To Challenge CMS PET Proposal

Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.

Medicare Panel Finds Little Support For Amyloid PET Imaging Changes

MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel